Clinical Interests
Breast cancer, cancer stem cell,chemoresistance, epigenetics
Experience
Post-doc, University of California LosAngeles David Geffen School of Medicine: Los Angeles, CA, US, 2017-09-14 to2019-07-14
Education
MD/PHD, Sichuan University West ChinaMedical Center: Chengdu, Sichuan, CN, 2004-09-01 to 2012-06-20 |
Professional memberships
American Society of Clinical Oncology:Alexandria, VA, US
Chinese Society of Clinical Oncology:Beijing, CN
Publications
1. Li Jieqing; Hao Qiongyu; CaoWei; Jaydutt V Vadgama*; Wu Yong*; Celecoxib in breast cancer prevention andtherapy., Cancer Management and Research, 2018, 10(10): 4653-4667.
2. Jieqing Li*; Diagnosis andTreatment of 75 Patients with Idiopathic Lobular Granulomatous Mastitis.,Journal of Investigative Surgery, 2018, 1(1): 1-7.
3. Yang, Mei; Fan, Yanhui; Wu,Zhi-Yong; Gu, Jin; Feng, Zhendong; Zhang, Qiangzu; Han, Shunhua; Zhang,Zhonghai; Li, Xu; Hsueh, Yi-Ching; Ni, Yanxiang; Li, Xiaoling; Li, Jieqing; Hu,Meixia; Li, Weiping; Gao, Hongfei; Yang, Ciqiu; Zhang, Chunming; Zhang, Liulu;Zhu, Teng; Cheng, Minyi; Ji, Fei; Xu, Juntao; Cui, Hening; Tan, Guangming;Zhang, Michael Q; Liang, Changhong; Liu, Zaiyi; Song, You-Qiang; Niu, Gang*;Wang, Kun*; DAGM: A novel modelling framework to assess the risk ofHER2-negative breast cancer based on germline rare coding mutations.,EBioMedicine, 2021, 69: 103446.
4. Hao, Qiongyu; Wang, Piwen;Dutta, Pranabananda; Chung, Seyung; Li, Qun; Wang, Kun; Li, Jieqing; Cao, Wei;Deng, Wenhong; Geng, Qing; Schrode, Katrina; Shaheen, Magda; Wu, Ke; Zhu,Donghui; Chen, Qiao-Hong; Chen, Guanglin; Elshimali, Yahya; Vadgama, Jay*; Wu,Yong*; Comp34 displays potent preclinical antitumor efficacy in triple-negativebreast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncodingRNA., Cell Death & Disease, 2020, 11(12): 1052.
5. Wenhong Deng; Jieqing Li;Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao;Zhaoxia Gao; Jay Vadgama; Yong Wu; The role of PPM1D in cancer and advances instudies of its inhibitors, Biomedicine & Pharmacotherapy, 2020, 125:109956.
6. Li, Qun; Hao, Qiongyu; Cao,Wei; Li, Jieqing; Wu, Ke; Elshimali, Yahya; Zhu, Donghui; Chen, Qiao Hong;Chen, Guanglin; Pollack, Jonathan R; Vadgama, Jay*; Wu, Yong*; PP2Cdeltainhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNAdamage response in breast cancer., Science Advances, 2019, 5(10): eaaw8417. CaoWei; Li Jieqing; Hao Qiongyu; Vadgama Jaydutt V*; Wu Yong*; AMP-activatedprotein kinase: a potential therapeutic target for triple-negative breastcancer., Breast Cancer Research, 2019, 21(1): 29.
